Mauno Vihinen does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
TT125-802, a highly selective, well-tolerated bromodomain inhibitor of CBP/p300 with anti-tumor activity in patients with advanced solid tumors: An update on the ongoing phase I study. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback